Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies security holder files a Form 144 notice to sell common stock. The filing covers a proposed sale of 11,081 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $174,636.56 and an approximate sale date of 01/12/2026.
The shares to be sold were acquired through stock option exercises, including 8,581 shares exercised for cash on 01/12/2026 and 2,500 shares previously exercised for cash on 03/14/2025. Over the past three months, the person for whose account the securities are to be sold has already sold common shares, including 162,820 shares on 11/28/2025 for gross proceeds of $3,174,534.10 and 238 shares on 11/17/2025 for $3,343.90, with one entry identified as 10b5-1 sales.
Adaptive Biotechnologies Corporation reported that it issued a press release with its financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report. The company also furnished an investor presentation, dated the same day, as Exhibit 99.2, which management may use in meetings with investors and analysts. Both the earnings release and the presentation are being furnished rather than filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on January 6, 2026. The sale was reported at a weighted average price of $16.44 per share. According to the disclosure, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. After this sale, he beneficially owned 1,222,312 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies officer Francis Lo, the Chief People Officer, reported option exercises and a related stock sale for company shares. On December 22, 2025, Lo exercised stock options to acquire 1,100 shares at $7.80, 1,100 shares at $8.46, and 2,194 shares at $3.99 per share, then sold 4,394 shares of common stock at a weighted-average price of $17.50. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo directly beneficially owned 315,978 shares of common stock and held additional indirect ownership of 2,500 shares through spouse You Jin Lee, along with multiple remaining stock option positions.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported selling 124,998 shares of the company’s common stock on January 5, 2026 at a weighted average price of $15.59 per share. After this sale, he beneficially owned 2,584,243 shares directly.
The transaction was coded as an open market or private sale and was carried out under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The filing notes that the shares were sold in multiple trades at prices ranging from $15.31 to $15.96, and that detailed trade-by-trade information is available upon request.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an option exercise and matching share sale under a pre-set trading plan. On January 2, 2026, Lo exercised a stock option for 3,125 shares of common stock at an exercise price of $3.99 per share and then sold 3,125 shares of common stock at a weighted-average price of $16.08 per share. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025, which is designed to structure trades in advance. After these transactions, Lo beneficially owned 315,978 shares of Adaptive Biotechnologies common stock directly and 2,500 shares indirectly through spouse You Jin Lee, along with 104,856 stock options that remain beneficially owned.
Adaptive Biotechnologies Corp’s Chief People Officer reported stock option exercises and a share sale. On December 15, 2025, the officer exercised options to acquire a total of 97,022 shares of common stock at exercise prices of $7.8, $8.46, and $3.99 per share. On the same date, 113,890 shares were sold in an open-market transaction at a weighted-average price of $15.57, with individual sale prices ranging from $15.37 to $16.03, all under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following these transactions, the reporting person directly beneficially owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse, and continued to hold multiple vested stock options.
Adaptive Biotechnologies director Robert Hershberg reported an open-market sale of company stock. On 12/10/2025, he sold 22,968 shares of Adaptive Biotechnologies common stock at a price of $16 per share.
Following this transaction, Hershberg now beneficially owns 46,722 shares of Adaptive Biotechnologies common stock, held directly. The filing identifies him as a director of the company and shows that the report was filed for a single reporting person.
Adaptive Biotechnologies (ADPT) reported insider transactions by its Chief Commercial Officer, Immune Medicine, Sharon Benzeno. On November 20–21, 2025, she executed multiple stock option exercises and related sales of common stock under a Rule 10b5-1 trading plan adopted on August 18, 2025.
She exercised options covering 133,032, 68,961, 834, 20,834, 49,480, 34,375, 119,809 and 83,145 shares at exercise prices between $3.99 and $12.14 per share, converting them into common stock. She then sold 297,925 shares at a weighted average price of $16.54 and 308,477 shares at a weighted average price of $16.91 in multiple transactions within stated price ranges.
Following these transactions, she directly beneficially owns 296,791 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp (ADPT) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO sold 238 shares of common stock at a price of $14.05 per share. After this transaction, the CFO beneficially owned 269,343 shares of Adaptive Biotechnologies common stock directly.
The company explains that this sale was made solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The transaction was carried out under the issuer’s equity incentive plan, which requires a mandatory "sell to cover" to satisfy tax obligations, so it was not a discretionary trade by the reporting person.